Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 78

1.

The impact of industry on oncology research and practice.

Moy B, Jagsi R, Gaynor RB, Ratain MJ.

Am Soc Clin Oncol Educ Book. 2015:130-7. doi: 10.14694/EdBook_AM.2015.35.130.

2.

Recognizing the Financial Burden of Cancer Patients in Clinical Trials.

Nipp RD, Powell E, Chabner B, Moy B.

Oncologist. 2015 Jun;20(6):572-5. doi: 10.1634/theoncologist.2015-0068. Epub 2015 May 18. No abstract available.

PMID:
25986245
3.

Clinical Trials, Disparities, and Financial Burden: It's Time to Intervene.

Moy B.

Oncologist. 2015 Jun;20(6):571. doi: 10.1634/theoncologist.2015-0137. Epub 2015 May 18. No abstract available.

PMID:
25986242
4.

Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).

Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Hudis C, Krop IE, Burstein HJ, Winer EP, Partridge AH, Tolaney SM.

Breast Cancer Res Treat. 2015 Jun;151(3):589-96. doi: 10.1007/s10549-015-3426-z. Epub 2015 May 16.

PMID:
25981899
5.

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.

Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE.

Breast Cancer Res. 2015 Apr 16;17:56. doi: 10.1186/s13058-015-0568-1.

6.

Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study.

Vaz-Luis I, Hughes ME, Cronin AM, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU.

Cancer. 2015 Jun 15;121(12):1937-48. doi: 10.1002/cncr.29310. Epub 2015 Mar 10.

PMID:
25757412
7.

Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer.

Boyle FM, Smith IE, O'Shaughnessy J, Ejlertsen B, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Amonkar M, Huang Y, Rappold E, Williams LS, Wang-Silvanto J, Kaneko T, Finkelstein DM, Goss PE; TEACH Investigators.

Eur J Cancer. 2015 Apr;51(6):685-96. doi: 10.1016/j.ejca.2015.02.005. Epub 2015 Mar 6.

PMID:
25752740
8.

Case records of the Massachusetts General Hospital. Case 1-2015. A 66-year-old woman with metastatic breast cancer after endocrine therapy.

Moy B, Specht MC, Lanuti M, Rafferty EA, Lerwill MF.

N Engl J Med. 2015 Jan 8;372(2):162-70. doi: 10.1056/NEJMcpc1408601. No abstract available.

PMID:
25564900
9.

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP.

N Engl J Med. 2015 Jan 8;372(2):134-41. doi: 10.1056/NEJMoa1406281.

10.

Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience.

Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, Stockerl-Goldstein K, Neumayer L, Langbaum TS, Theriault RL, Hughes ME, Weeks JC, Karp JE.

J Clin Oncol. 2015 Feb 1;33(4):340-8. doi: 10.1200/JCO.2013.54.6119. Epub 2014 Dec 22. Erratum in: J Clin Oncol. 2015 Apr 1;33(10):1227.

PMID:
25534386
11.

American Society of Clinical Oncology policy statement on medicaid reform.

Polite BN, Griggs JJ, Moy B, Lathan C, duPont NC, Villani G, Wong SL, Halpern MT.

J Clin Oncol. 2014 Dec 20;32(36):4162-7. doi: 10.1200/JCO.2014.56.3452. Epub 2014 Nov 17. No abstract available.

PMID:
25403206
12.

Debating the oncologist's role in defining the value of cancer care: our duty is to our patients.

Sulmasy D, Moy B.

J Clin Oncol. 2014 Dec 20;32(36):4039-41. doi: 10.1200/JCO.2014.57.8716. Epub 2014 Nov 3. No abstract available.

PMID:
25366686
13.

Gene deletions in Mycobacterium bovis BCG stimulate increased CD8+ T cell responses.

Panas MW, Sixsmith JD, White K, Korioth-Schmitz B, Shields ST, Moy BT, Lee S, Schmitz JE, Jacobs WR Jr, Porcelli SA, Haynes BF, Letvin NL, Gillard GO.

Infect Immun. 2014 Dec;82(12):5317-26. doi: 10.1128/IAI.02100-14. Epub 2014 Oct 6.

14.

Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, Gralow J, Hortobagyi GN, Moy B, Yee D, Brundage SB, Danso MA, Wilcox M, Smith IE.

J Clin Oncol. 2014 Oct 10;32(29):3307-29. doi: 10.1200/JCO.2014.56.7479. Epub 2014 Sep 2.

PMID:
25185096
15.

Measuring decision quality: psychometric evaluation of a new instrument for breast cancer chemotherapy.

Lee CN, Wetschler MH, Chang Y, Belkora JK, Moy B, Partridge A, Sepucha KR.

BMC Med Inform Decis Mak. 2014 Aug 20;14:73. doi: 10.1186/1472-6947-14-73.

16.

Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.

Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU.

J Clin Oncol. 2014 Jul 10;32(20):2142-50. doi: 10.1200/JCO.2013.53.1608. Epub 2014 Jun 2.

17.

Value of cancer care: ethical considerations for the practicing oncologist.

Jagsi R, Sulmasy DP, Moy B.

Am Soc Clin Oncol Educ Book. 2014:e146-9. doi: 10.14694/EdBook_AM.2014.34.e146.

18.

Geriatric oncology for the 21st century: a call for action.

Moy B, Flaig TW, Muss HB, Clark B, Tse W, Windham TC.

J Oncol Pract. 2014 Jul;10(4):241-3. doi: 10.1200/JOP.2013.001333. Epub 2014 Apr 29. No abstract available.

19.

Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I.

Oncologist. 2014 Apr;19(4):348-9. doi: 10.1634/theoncologist.2014-0021. Epub 2014 Mar 27.

20.

Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I.

Oncologist. 2014 Apr;19(4):346-7. doi: 10.1634/theoncologist.2014-0022. Epub 2014 Mar 27.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk